Idiopathic Pulmonary Fibrosis Cohort of TCM
Condition(s) studied
Investigational drug(s) / intervention(s)
Traditional Chinese medicine (TCM): Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Exposure is defined as taking the medication continuously for more than 3 months per year, or intermittently for more than 6 months per year. According to the standardised use of TCM protocols, the group is divided into an exposed group (TCM cohort) and an unexposed group (non-TCM cohort).
Non-traditional Chinese medicine (non-TCM): All intervention measures that do not meet the criteria for TCM exposure are regarded as non-TCM exposure.
Study summary
This study, based on past registration records, evaluates the clinical efficacy of traditional Chinese medicine in treating IPF in the real world, identifies advantageous populations and clinical targets, and provides references for precision traditional Chinese medicine treatment.
Eligibility
Primary outcome measure(s)
- Annual acute exacerbation rate — Up to week 104
The annual acute exacerbation rate will be calculated in each group at the end of the trial.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| The First Affiliated Hospital of Henan University of Chinese Medicine | Zhengzhou | Henan |
More Henan University of Traditional Chinese Medicine trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07162870 on ClinicalTrials.gov ↗ ← All trials in China